Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Olema Pharmaceuticals (OLMA – Research Report). The associated price target remains the same with $27.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sam Slutsky’s rating is based on Olema Pharmaceuticals’ promising development pipeline, particularly in the treatment of ER+ breast cancer. The company has shown progress with its Phase 1b/2 study of palazestrant (OP-1250) in combination with Kisqali, which targets advanced ER+ breast cancer patients. The anticipation of mature data from this study, expected to be shared at a medical meeting in 2025, adds to the positive outlook.
Additionally, Olema’s strategic plans for 2025, including the initiation of the Phase 3 OPERA-02 trial, further support the Buy rating. This trial will test the efficacy of palazestrant combined with Kisqali for first-line ER+ breast cancer treatment. The company’s focus on execution and upcoming data releases, which could impact their development pipeline, are key factors in the Buy recommendation.